#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Myotonic dystrophy Glomerulonephritis minimal lesion Renal cell carcinoma Cardiomyopathy Prostate cancer Hyperinsulinaemic hypoglycaemia Thalassaemia Heavy menstrual bleeding Amyloidosis Ovarian epithelial cancer Myasthenia gravis Antiphospholipid syndrome Factor VIII deficiency Thrombocytopenia Graft versus host disease More trials…

    Learn about Rare Diseases

    Mantle cell lymphoma refractory – Diagnostics Arterial tortuosity syndrome – Treatment Focal segmental glomerulosclerosis – Trials in Disease Lysosomal storage disorder – Treatment Brain stem glioma – Trials in Disease Retinitis pigmentosa – Basic Information Angelman’s syndrome – Treatment Wolfram syndrome – Basic Information Haemophilia B with anti factor IX – Basic Information Turner’s syndrome – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Adalimumab Codeine Phosphate Caplacizumab Potassium Oxybate NORETHISTERONE ACETATE Amy109 Cctx-001 Omalizumab Betamethasone Nicotine Natalizumab 6QC-ICG Bevacizumab Zirconium Zr-89 Fludrocortisone Human Cancellous Bone AZD4512 Cft1946 Cd7-Cart01 Lenomorelin Vinorelbine Tartrate More therapies…

    Learn about Your Condition

    Marginal zone lymphoma K-ras gene mutation Epithelioid sarcoma Thymoma Retroperitoneal fibrosis Dyspepsia Urinary incontinence Osteoporosis postmenopausal Hyperphagia Cervix carcinoma stage IV Metastases to meninges Leber's congenital amaurosis Cognitive disorder Connective tissue disorder Pulmonary sarcoidosis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Primary amyloidosis

  • Study on Safe Skin Test Concentrations for Biotherapy Allergies in Patients with Cancer Using Atezolizumab, Daratumumab, and Nivolumab

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Pleural mesothelioma
    • Primary amyloidosis
    • Malignant melanoma
    Investigated Drugs:
    • Atezolizumab
    • Cemiplimab
    • Daratumumab
    France

  • Study on the Safety and Effectiveness of Linvoseltamab, Sarilumab, and Dexamethasone in Adults with Relapsed or Refractory AL Amyloidosis

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Primary amyloidosis
    Investigated Drugs:
    • Sarilumab
    • Diphenhydramine Hydrochloride
    • Linvoseltamab
    Greece Spain

  • Study of Teclistamab for Patients with Previously Treated AL Amyloidosis

    Not recruiting

    2 1 1
    Investigated Drugs:
    • Teclistamab
    France Germany Greece Italy The Netherlands

  • Study on the Safety and Effectiveness of Sargramostim with Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone in Untreated Light Chain Amyloidosis Patients

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Primary amyloidosis
    Investigated Drugs:
    • Dexamethasone Phosphate
    • Bortezomib
    • Cyclophosphamide
    Poland

  • Study on the Effectiveness and Safety of CAEL-101 with Drug Combination for Patients with Advanced AL Amyloidosis

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Anselamimab
    • Sodium Hydrogen Carbonate Pheur
    • Sodium Chloride Ph. Eur.
    Austria Belgium Czechia France Germany Greece +3

  • Study on the Effectiveness and Safety of CAEL-101 with Plasma Cell Dyscrasia Treatment in Patients with Stage IIIa AL Amyloidosis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Primary amyloidosis
    • Cardiac amyloidosis
    Investigated Drugs:
    • Anselamimab
    • Sodium Hydrogen Carbonate Pheur
    • Sodium Chloride Ph. Eur.
    Austria Czechia France Germany Greece Italy +2
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!